MedTrace Logo

Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia

NCT02690246 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 915

Last updated 2022-03-22

No results posted yet for this study

Summary

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. The purpose of this study is to provide data about multiple clinical aspects of HHT and responses to treatment. For comparison of some aspects also data of non-affected relatives is collected (second cohort). the questionnaire has been designed primarily for web based entry, but can also be circulated in paper format on request.

Conditions

  • Hereditary Haemorrhagic Telangiectasia (HHT)

Interventions

OTHER

questionnaire

a questionnaire based study

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Urban Geisthoff, Prof. Dr. · University Hospital, Essen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2019-08-31
Completion
2021-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02690246 on ClinicalTrials.gov